First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 96
Trials in obesity and other serious chronic disease areas
building on the semaglutide molecule
Planned or ongoing trials with semaglutide
addressing other serious chronic diseases
Ongoing phase 2 trial with daily semaglutide vs
placebo in patients with NASH
semaglutide
Obesity
NASH
CVD
CKD
semaglutide 0.4 mg sc QD
372
patients¹
semaglutide 0.2 mg sc QD
semaglutide 0.1 mg sc QD
Placebo 0.1, 0.2 or 0.4 mg
Liver biopsy
(recent or new)
72 weeks
Liver biopsy
Next steps:
Phase 2 trial expected to complete 2020
CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic kidney disease
changing
diabetes®
1 Inclusion criteria: Histological confirmation of NASH, BMI 25-45 kg/m², NASH fibrosis
stage 2 or 3, Histological NAFLD Activity Score ≥ 4
mg: Milligram; sc: Subcutaneous; QD: Once-daily; MR: Magnetic resonance;
NAFLD: Non-alcoholic fatty liver disease
novo nordiskView entire presentation